Addressing Discrimination and False Cures in Type 1 Diabetes: What we can learn from HIV Rights-based Response
India has the second-highest number of children with Type 1 diabetes globally. Almost a million Indians living with T1D face stigma and discrimination rooted in myths and stereotypes. With the health ministry and NCD programme failing to ensure equitable access to treatment and monitoring tools, could learnings from HIV/AIDs response help evolve legal norms against discrimination and misinformation on Type 1 diabetes?
Leena Menghaney
Published on: 21 April 2026, 11:55 am
INDIA HOSTED the first Global Summit to End Diabetes Stigma in Jaipur in March 2026. One of the main themes was the application of human rights law to address diabetes-related stigma in healthcare, education, and employment. The key question that emerged was this: what lessons can be drawn from the HIV rights-based response in combating discrimination and misinformation?
People living with Type 1 diabetes (‘T1D’) continue to face stigma and discrimination rooted in myths, stereotypes, and a persistent misunderstanding of this autoimmune condition, often diagnosed in childhood, adolescence or as young adults. Parents are frequently confronted with misleading claims—particularly so-called “cures”—that exploit their vulnerability and create confusion about effective treatment.
Children with T1 diabetes and learnings from HIV response
For children, these dynamics translate into direct violations of legal rights. There are documented instances of schools refusing admission upon disclosure of T1D in admission forms—constituting an abuse of disclosed medical information to exclude children with T1D and an infringement of the child’s right to education. Even where admission is granted, schools often impose disproportionate and discriminatory conditions, such as requiring a parent—typically the mother—to remain in school due to perceived risks associated with insulin administration or medical emergencies.
These practices point to a clear regulatory and policy gap. The Central Advisory Board of Education (‘CABE’), India’s highest advisory body that advises central and state governments on education policy, lacks guidance to govern admission practices and the schools’ duty of care toward children with chronic conditions such as T1D. At the same time, there is inadequate coordination with the Ministry of Health and Family Welfare (‘MoHFW’) and its National Programme for Prevention and Control of Non-Communicable Diseases (‘NCD Programme’) to ensure early screening in schools and access of children with T1D to essential diabetes management tools. These include insulin pens and continuous glucose monitoring devices (‘CGMs’) which facilitate their management and reduce the opportunities for exclusion from attendance and activities in both public and private school settings. The result is a de facto exclusion from education for many children with T1D.
